Semglee (insulin glargine biosimilar)
Diabetes
ApprovedCommercial
Key Facts
About Viatris
Viatris is one of the world's largest generic and specialty pharmaceutical companies, created through the transformational merger of Mylan and Pfizer's Upjohn business. The company operates across four key pillars: generics, complex generics, biosimilars, and established brands, with a mission to empower people worldwide to live healthier at every stage of life. Viatris maintains a global manufacturing footprint with facilities across multiple continents and has established itself as a leader in access to medicines worldwide.
View full company profileTherapeutic Areas
Other Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Toujeo | Sanofi | Commercial |
| Lantus | Sanofi | Commercial |
| Semglee (Insulin Glargine) | Biocon | Approved |
| Insulin Aspart | Biocon | Phase 3 |
| Liraglutide | Biocon | Phase 3 |
| MK-1293 (insulin glargine biosimilar) | Organon | Approved/Filed |
| Insulin Glargine (Biosimilar) | Gulf Pharmaceutical Industries | Approved/Commercial |
| CYAPO913 | FibroBiologics | Discovery |